Skip to main content
. Author manuscript; available in PMC: 2015 Aug 13.
Published in final edited form as: Cochrane Database Syst Rev. 2014 Aug 13;8:CD003256. doi: 10.1002/14651858.CD003256.pub2

Comparison 4. HAART + paclitaxel versus HAART + pegylated liposomal doxorubicin (RCT).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Progression of KS 1 49 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.07, 15.73]
2 Clinical response 1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
 2.1 Complete response 1 49 Risk Ratio (M-H, Fixed, 95% CI) 2.08 [0.20, 21.50]
 2.2 Partial response 1 49 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.50, 2.17]
 2.3 Stable disease 1 49 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.27, 1.45]